ClinicalTrials.gg
CompletedNCT03605836Updated Oct 18, 2021Results posted

A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

A Phase 3 interventional study of Centanafadine SR and Placebo in Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-10-18.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
590
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity — 5 open to participants now, 5 under way, 5 of them phase 3. centanafadine · Attention Deficit Disorder with Hyperactivity.

Enrollment
5th of 20
590 · median 180
Started
2019
with 3 others
Phase 3
10 of 20
3 open now
Registered
3rd of 20
by date
Lead sponsor
16 of 20
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity, this one is the 5th largest by enrollment, is one of 4 that started in 2019, is one of 10 in phase 3, and was the 3rd registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

5 of the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About centanafadine

centanafadine: first FDA approval 2026 (SIMTRIYO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

This study evaluated the efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with ADHD. Participants either received a twice-daily dose of centanafadine sustained-release tablets, or twice-daily placebo.

Read the detailed description

Screening \& Washout Period: up to 28 days Investigational Treatment Period: 49 days Follow-up Period : 7 days or 10 days

03

Conditions studied

  • Attention Deficit Disorder
  • Attention Deficit Hyperactivity Disorder

Keywords

  • Centanafadine
  • ADD
  • ADHD
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet the Fifth Edition (DSM-5) criteria for ADHD (including predominantly inattentive presentation, hyperactive presentation, or combined presentation) as confirmed by the Adult ADHD Clinical Diagnostic Scale (ACDS) Version 1.2. To confirm that ADHD is the primary diagnosis, the Mini International Neuropsychiatric Interview (MINI) will be used to identify and exclude other psychiatric conditions which would preclude enrollment.
  • Participants who were not receiving any pharmacological treatment for ADHD must have an Adult ADHD Investigator Symptom Rating Scale (AISRS) score of ≥ 28 at screening and baseline. Participants who were receiving pharmacological treatment for ADHD at screening must have a minimum AISRS score of ≥ 22 at screening, and a score of ≥ 28 at baseline.
  • All participants must be willing to discontinue all prohibited psychotropic medications starting from the time of signing the through the 7-day follow-up period. Participants that do not rollover into Trial 405-201-00015 must be willing to discontinue all prohibited psychotropic medications starting from the time of signing the informed consent until after the follow-up telephone call 10 days after the last dose of IMP.
  • Participants must have a Clinical Global Impression-Severity of Illness Scale (CGI-S) score of ≥ 4 (≥ moderate impairment) at baseline.

Exclusion criteria

Exclusion Criteria:

  • Participant has a Diagnosis of Other Specified or Unspecified Attention Deficit/Hyperactivity Disorder.
  • Participant has a current comorbid psychiatric disorder that either could be expected to require treatment with medications prohibited in this trial, or to confound efficacy or safety assessments. Examples include, but are not limited to, psychotic disorder, bipolar disorder, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, a current major depressive episode, or posttraumatic stress disorder, as established by the MINI.
  • In the opinion of the investigator, participants has not derived significant therapeutic benefit from 2 or more ADHD therapies of 2 different classes (eg, amphetamine and methylphenidate) given with an acceptable dose and duration of adulthood (aged 18 or older). NOTE: If participants has not derived significant therapeutic benefit due to an inability to tolerate side effects, eligibility can be discussed on case-by-case basis with the medical monitor.
  • Participants who have a positive alcohol test (via breathalyzer or blood), a positive drug screen assessed prior to the baseline visit for cocaine, other illicit drugs (including marijuana), or prescription or OTC ADHD medications will be early terminated. This includes medications such as opioids or benzodiazepines taken without prescription.
  • In the opinion of the investigator, the participants is unable to adhere to the treatment regimen or other requirements outlined in the protocol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
590 participants (actual)

Study arms

  • Experimental
    Single-blind Run-in Period: Placebo

    Placebo-matching tablets BID (twice daily) on Day -7 through Baseline (Day -1).

    Other: Placebo

  • Experimental
    Double-blind Treatment Period: Centanafadine SR 200 mg

    Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 200 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.

    Drug: Centanafadine SR

  • Experimental
    Double-blind Treatment Period: Centanafadine SR 400 mg

    Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 400 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.

    Drug: Centanafadine SR

  • Placebo comparator
    Double-blind Treatment Period: Placebo

    Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine SR matching placebo tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.

    Other: Placebo

Interventions

  • 100 mg, BID, oral tablets

    Also known as: EB-1020

  • OtherPlacebo

    BID, oral tablet

  • 200 mg, BID, oral tablets

    Also known as: EB-1020

06

What researchers measure

Primary outcomes

  1. Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS) Score at Day 42

    The AISRS is an 18-item clinician rating scale to evaluate individual ADHD symptoms on a scale of 0 (none) to 3 (severe). The total sum ranges from 0 (no ADHD symptoms) to 54 (extremely severe ADHD symptoms). Mixed-effect model repeated measure (MMRM) was used for the analysis.

    Time frame: Baseline and Day 42

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S) Score at Day 42

    CGI-S is an observer-rated scale used to measure symptom severity with a total score range of 0 to 7 where 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A negative change from Baseline indicates improvement. MMRM was used for the analysis.

    Time frame: Baseline and Day 42

Other outcomes

  1. Adverse Event Reporting

    Frequency and severity of treatment-emergent adverse events (TEAEs) will be assessed to determine safety and tolerability of centanafadine SR tablets

    Time frame: Up to 59 days

  2. ADHD Impact Module - Adult (AIM-A)

    Scale composed of 3 subscales with a maximum score of 100. A lower score indicates a worse outcome. Exploratory endpoint; comparison of baseline score to other points throughout the study.

    Time frame: Up to 42 days

  3. Adult ADHD Self Report Scale (ASRS)

    An 18 question report, total score ranges from 0 to 124. A higher score denotes a worse outcome. Exploratory endpoint; comparison of baseline score to other points throughout the study

    Time frame: Up to 42 days

  4. AISRS

    Change from baseline total score compared to every scheduled visit. Each subscale is composed of 9 items each. Scores can range from 0 to 27, with a higher score representing a worse outcome. Change from baseline scores are compared to every scheduled visit score.

    Time frame: Up to 42 days

07

Results

Posted Oct 18, 2021

Participant flow

Participants took part in the study at 48 investigative sites in the United States from 16 January 2019 to 14 May 2020.

OL Placebo Run-in Period [1 Week]
Participant flow — OL Placebo Run-in Period [1 Week]
MilestoneSingle-blind Run-in Period: PlaceboDouble-blind Treatment Period: Centanafadine SR 200 mgDouble-blind Treatment Period: Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo
Started590000
Treated579000
Completed440000
Not completed150000
Withdrew: Adverse event2000
Withdrew: Lack of efficacy2000
Withdrew: Lost to follow-up8000
Withdrew: Non-compliance with study drug4000
Withdrew: Protocol deviation4000
Withdrew: Withdrawal by subject17000
Withdrew: Site terminated by sponsor5000
Withdrew: Physician decision7000
Withdrew: Reason not related to covid-1985000
Withdrew: Covid-19 related15000
Withdrew: Discontinued prior to the treatment.1000
Double-blind Treatment Period [6 Weeks]
Participant flow — Double-blind Treatment Period [6 Weeks]
MilestoneSingle-blind Run-in Period: PlaceboDouble-blind Treatment Period: Centanafadine SR 200 mgDouble-blind Treatment Period: Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo
Started0147147146
Treated0145143142
Completed0111102123
Not completed0364523
Withdrew: Randomized but not treated in double-blind treatment period0244
Withdrew: Adverse event0580
Withdrew: Lack of efficacy0021
Withdrew: Lost to follow-up0351
Withdrew: Non-compliance with study drug0104
Withdrew: Pregnancy0100
Withdrew: Protocol deviation0511
Withdrew: Withdrawal by subject01064
Withdrew: Physician decision0310
Withdrew: Reason not specified06167
Withdrew: Covid-19 related0021

Outcome measures

PrimaryChange From Baseline in ADHD Investigator Symptom Rating Scale (AISRS) Score at Day 42

The AISRS is an 18-item clinician rating scale to evaluate individual ADHD symptoms on a scale of 0 (none) to 3 (severe). The total sum ranges from 0 (no ADHD symptoms) to 54 (extremely severe ADHD symptoms). Mixed-effect model repeated measure (MMRM) was used for the analysis.

Time frame:
Baseline and Day 42
Reported as:
Least squares mean · score on a scale
Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS) Score at Day 42
score on a scaleDouble-blind Treatment Period: Centanafadine SR 200 mgDouble-blind Treatment Period: Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo
Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS) Score at Day 42-12.1 ± 0.96-12.5 ± 0.99-8.07 ± 0.94
Statistical analysis
  • Double-blind Treatment Period: Centanafadine SR 200 mg vs Double-blind Treatment Period: Placebo · MMRM · p = =0.0021 · Least squares (ls) mean difference: -4.01 · 95% CI -6.55 to -1.46The comparison between the centanafadine and the placebo group was tested at a significance level of 0.05.
  • Double-blind Treatment Period: Centanafadine SR 400 mg vs Double-blind Treatment Period: Placebo · MMRM · p = =0.0009 · Ls mean difference: -4.42 · 95% CI -7.02 to -1.82The comparison between the centanafadine and the placebo group was tested at a significance level of 0.05.
SecondaryChange From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S) Score at Day 42

CGI-S is an observer-rated scale used to measure symptom severity with a total score range of 0 to 7 where 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A negative change from Baseline indicates improvement. MMRM was used for the analysis.

Time frame:
Baseline and Day 42
Reported as:
Least squares mean · score on a scale
Change From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S) Score at Day 42
score on a scaleDouble-blind Treatment Period: Centanafadine SR 200 mgDouble-blind Treatment Period: Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo
Change From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S) Score at Day 42-1.04 ± 0.09-0.99 ± 0.09-0.71 ± 0.09
Statistical analysis
  • Double-blind Treatment Period: Centanafadine SR 200 mg vs Double-blind Treatment Period: Placebo · MMRM · p = =0.0073 · Ls mean difference: -0.33 · 95% CI -0.57 to -0.09The comparison between the centanafadine and the placebo group was tested at a significance level of 0.05.
  • Double-blind Treatment Period: Centanafadine SR 400 mg vs Double-blind Treatment Period: Placebo · MMRM · p = =0.0245 · Ls mean difference: -0.28 · 95% CI -0.53 to -0.04The comparison between the centanafadine and the placebo group was tested at a significance level of 0.05.
Other pre-specifiedAdverse Event Reporting

Frequency and severity of treatment-emergent adverse events (TEAEs) will be assessed to determine safety and tolerability of centanafadine SR tablets

Time frame:
Up to 59 days

Results for this outcome have not been posted.

Other pre-specifiedADHD Impact Module - Adult (AIM-A)

Scale composed of 3 subscales with a maximum score of 100. A lower score indicates a worse outcome. Exploratory endpoint; comparison of baseline score to other points throughout the study.

Time frame:
Up to 42 days

Results for this outcome have not been posted.

Other pre-specifiedAdult ADHD Self Report Scale (ASRS)

An 18 question report, total score ranges from 0 to 124. A higher score denotes a worse outcome. Exploratory endpoint; comparison of baseline score to other points throughout the study

Time frame:
Up to 42 days

Results for this outcome have not been posted.

Other pre-specifiedAISRS

Change from baseline total score compared to every scheduled visit. Each subscale is composed of 9 items each. Scores can range from 0 to 27, with a higher score representing a worse outcome. Change from baseline scores are compared to every scheduled visit score.

Time frame:
Up to 42 days

Results for this outcome have not been posted.

Adverse events

Collected over Up to 59 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo: Single-blind Run-in Period Only0/149 (0%)0/149 (0%)9/149 (6%)
Placebo + Centanafadine SR 200 mg0/145 (0%)1/145 (0.7%)31/145 (21.4%)
Placebo + Centanafadine SR 400 mg0/143 (0%)0/143 (0%)47/143 (32.9%)
Placebo + Placebo0/142 (0%)0/142 (0%)24/142 (16.9%)
Most frequent serious events
Most frequent serious events
EventPlacebo: Single-blind Run-in Period OnlyPlacebo + Centanafadine SR 200 mgPlacebo + Centanafadine SR 400 mgPlacebo + Placebo
BronchitisInfections and infestations0/1491/1450/1430/142
Most frequent other events
Most frequent other events
EventPlacebo: Single-blind Run-in Period OnlyPlacebo + Centanafadine SR 200 mgPlacebo + Centanafadine SR 400 mgPlacebo + Placebo
NauseaGastrointestinal disorders3/1495/14515/1433/142
HeadacheNervous system disorders5/14911/14515/1438/142
Decreased ApettiteMetabolism and nutrition disorders1/1496/14510/1433/142
Dry MouthGastrointestinal disorders1/1493/1459/1431/142
Upper Respiratory Tract InfectionInfections and infestations1/1499/1455/1435/142
DiarrhoeaGastrointestinal disorders0/1494/1458/1433/142
InsomniaPsychiatric disorders1/1493/1458/1433/142

Baseline characteristics

Participants who participated only in the Run-in Period and Full Analysis Set (FAS) of the Double-blind Treatment Period including all participants of the safety sample of Double-blind Treatment Period who had a Baseline value and at least one valid post-randomization efficacy evaluation for adult ADHD investigator symptom rating scale (AISRS) total score in the Double-blind Treatment Period.

Age, Continuous
Age, Continuous(years)Placebo: Single-blind Run-in Period OnlyDouble-blind Treatment Period: Placebo + Centanafadine SR 200 mgDouble-blind Treatment Period: Placebo + Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo + PlaceboTotal
Mean33.7 ± 9.634.5 ± 9.735.2 ± 10.435.2 ± 9.634.6 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Placebo: Single-blind Run-in Period OnlyDouble-blind Treatment Period: Placebo + Centanafadine SR 200 mgDouble-blind Treatment Period: Placebo + Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo + PlaceboTotal
Female70717066277
Male80767780313
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo: Single-blind Run-in Period OnlyDouble-blind Treatment Period: Placebo + Centanafadine SR 200 mgDouble-blind Treatment Period: Placebo + Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo + PlaceboTotal
Hispanic or Latino30272329109
Not Hispanic or Latino119117122116474
Unknown or Not Reported13217
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo: Single-blind Run-in Period OnlyDouble-blind Treatment Period: Placebo + Centanafadine SR 200 mgDouble-blind Treatment Period: Placebo + Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo + PlaceboTotal
American Indian or Alaska Native00224
Asian4102622
Native Hawaiian or Other Pacific Islander11002
Black or African American2617192183
White116112120114462
More than one race00000
Unknown or Not Reported374317
Adult Attention-deficit/Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale(AISRS) Score
Adult Attention-deficit/Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale(AISRS) Score(score on a scale)Placebo: Single-blind Run-in Period OnlyDouble-blind Treatment Period: Placebo + Centanafadine SR 200 mgDouble-blind Treatment Period: Placebo + Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo + PlaceboTotal
Mean—37.6 ± 6.738.6 ± 7.037.8 ± 6.538.0 ± 6.7
Clinical Global Impression-Severity of Illness Scale (CGI-S) Score
Clinical Global Impression-Severity of Illness Scale (CGI-S) Score(score on a scale)Placebo: Single-blind Run-in Period OnlyDouble-blind Treatment Period: Placebo + Centanafadine SR 200 mgDouble-blind Treatment Period: Placebo + Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo + PlaceboTotal
Mean—4.6 ± 0.64.6 ± 0.54.5 ± 0.64.6 ± 0.6
08

Study locations

1 site
  • For additional information regarding sites, contact 844-687-8522
    Orlando, Florida 32806, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in May 2020, 15 months.

Results were first posted in Oct 2021, 1 year 5 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 15 months is above that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2018
First posted
Jul 30, 2018
StartActual
Jan 16, 2019
Primary completionActual
May 14, 2020
CompletionActual
May 14, 2020
Results first posted
Oct 18, 2021
Last update
Oct 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03605836
Responsible party
Sponsor
First posted
Jul 30, 2018
Start date
Jan 16, 2019
Primary completion
May 14, 2020
Completion
May 14, 2020
Results posted
Oct 18, 2021
Last update
Oct 18, 2021

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Centanafadine

Start the discussion